Abstract: A cushion for decompressing the human spinal column comprises a body support surface, a first short flat bottom surface, a longer second flat bottom surface, wherein the first bottom surface and the second bottom surface intersect and are angled at a particular angle lying within the range of 120 degrees to 150 degrees, but preferably at 135 degrees. A cushion for decompressing the human spinal column comprise a body support surface, and a curved bottom surface wherein the curve of the bottom surface increases or decreases in radius from one end to the other. The curve of the bottom surface may have the shape of an incomplete portion of a two-dimensional spiral.

Abstract: A convertible shoe having a shoe body and a shoe sole. An air channel formed in said shoe sole including pressurized air inlet and air exhaust. An elongated pocket or multiple individual pockets in the bottom of the shoe sole and along said air channel. A flexible wall portion between said air channel and pocket that expands into the pocket(s) upon pressurization of said air channel. A protrusion affixed to said flexible wall portion and which extends out of said pocket and into engagement with a support surface when said air channel is pressurized.

Abstract: A convertible shoe having a shoe body and a shoe sole. An air channel formed in said shoe sole including pressurized air inlet and air exhaust. An elongated pocket or multiple individual pockets in the bottom of the shoe sole and along said air channel. A flexible wall portion between said air channel and pocket that expands into the pocket(s) upon pressurization of said air channel. A protrusion affixed to said flexible wall portion and which extends out of said pocket and into engagement with a support surface when said air channel is pressurized.

Abstract: A convertible shoe having a shoe body and a shoe sole. An air channel formed in said shoe sole including pressurized air inlet and air exhaust. An elongated pocket or multiple individual pockets in the bottom of the shoe sole and along said air channel. A flexible wall portion between said air channel and pocket that expands into the pocket(s) upon pressurization of said air channel. A protrusion affixed to said flexible wall portion and which extends out of said pocket and into engagement with a support surface when said air channel is pressurized.

Abstract: This invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition; a method of treating a disease mediated by an MMP-13 enzyme in a mammal; and a therapeutic combination containing at least two pharmaceutically active components, wherein R1, Q, W1, W2, R2a, L1, and R3, the pharmaceutical composition, the method of treating, and the therapeutic combination are as defined in the specification.

Abstract: This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions and methods of treating diseases.

Abstract: This invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition; a method of treating a disease mediated by an MMP-13 enzyme in a mammal; and a therapeutic combination containing at least two pharmaceutically active components, wherein R1, Q, W1, W2, W2a, R3a, R3b, L1, and L2, the pharmaceutical composition, the method of treating, and the therapeutic combination are as defined in the specification.

Abstract: A tire in which a tire manufacturer has determined the tractive capacity at numerous levels of tread wear, the tire having at least one visual warning indicator located at a tread depth corresponding to a percentage loss of tractive capacity. Also, a method of making the tire and a method improving traffic safety through use of such a tire combined with educating the consumer as to proper use of the tire.

Abstract: A convertible shoe having a shoe body and a shoe sole. An air channel formed in said shoe sole including pressurized air inlet and air exhaust. An elongated pocket or multiple individual pockets in the bottom of the shoe sole and along said air channel. A flexible wall portion between said air channel and pocket that expands into the pocket(s) upon pressurization of said air channel. A protrusion affixed to said flexible wall portion and which extends out of said pocket and into engagement with a support surface when said air channel is pressurized.

Abstract: This invention provides compounds defined by Formula I and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of treating osteo- and rheumatoid arthritis.

Abstract: Selective MMP-13 inhibitors are pyridine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are hydrogen, halo, hydroxy, C1–C6 alkyl, C1–C6 alkoxy, C2–C6 alkenyl, C2–C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H, C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is an integer of from 0 to 6.

Abstract: The present invention provides compounds of formula (I) wherein R, Z, Y, W, R5, V, and X are as defined in the description, and pharmaceutically acceptable salts thereof, which are useful for the treatment of diseases responsive to the inhibition of the enzyme 15-lipoxygenase. Thus, the compounds of formula (I) and their pharmaceutically acceptable salts are useful for treating diseases with an inflammatory component, including atherosclerosis, diseases involving chemotaxis of monocytes, inflammation, stroke, coronary artery disease, asthma, arthritis, colorectal cancer, and psoriasis.

Abstract: The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula I More particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.

Abstract: Selective MMP-13 inhibitors are pyridine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3, E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted, n is an integer of from 0 to 6.

Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, or a tautomer thereof, wherein G1, G2, and B are as defined in the application, are selective inhibitors of MMP-13. The compounds are useful for treating diseases mediated by MMP-13, including cancer and arthritis.

Abstract: Selective MMP-13 inhibitors are pyridine derivatives of the formula 1

Abstract: The present invention provides compounds of formula (I) wherein R, Z, Y, W, R5, V, and X are as defined in the description, and pharmaceutically acceptable salts thereof, which are useful for the treatment of diseases responsive to the inhibition of the enzyme 15-lipoxygenase. Thus, the compounds of formula (I) and their pharmaceutically acceptable salts are useful for treating diseases with an inflammatory component, including atherosclerosis, diseases involving chemotaxis of monocytes, inflammation, stroke, coronary artery disease, asthma, arthritis, colorectal cancer, and psoriasis.

Abstract: This invention provides compounds defined by Formula I 1

Abstract: This invention provides compounds defined by Formula I 1

Abstract: This invention provides compounds defined by Formula I 1